Jennifer Michaelson sold $165k of CGEM
Chief Scientific Officer at Cullinan Oncology, Inc.. 11,742 shares at an average of $14.08, traded Feb 20, 2026, filed Feb 23, 2026.
Score components
- +15RoleOfficer
- +11Trade size$165k at market
- 0Share of holdings soldSold 6.3% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.5%, 3m -1.1%, 6m +56.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-064256, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | SOpen-market sale Common Stock10b5-1 | -3,742 | $13.62 | $51k | 181,977 | Feb 23, 2026 |
| Feb 20, 2026 | MOption exercise Common Stock10b5-1 | +8,000 | $4.30 | $34k | 189,977 | Feb 23, 2026 |
| Feb 20, 2026 | SOpen-market sale Common Stock10b5-1 | -8,000 | $14.30 | $114k | 181,977 | Feb 23, 2026 |
| Feb 20, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 124,987 | Feb 23, 2026 |
Related signals
Other insiders at Cullinan Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $173k 8,000 shares | -5% | |
| 5Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $608k 30,000 shares | -16% | |
| 0Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $143k 8,000 shares | -5% | |
| 0Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $117k 8,000 shares | -5% | |
| 6Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $125k 8,000 shares | -4% | |
| 15Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $25k 1,780 shares | -1% | |
| 52Moderate | Cullinan Oncology, Inc. | Nadim Ahmed President and CEO | $196k 13,515 shares | -3% | |
| 37Weak | Cullinan Oncology, Inc. | Jacquelyn L Sumer Chief Legal Officer | $52k 3,601 shares | -3% | |
| 38Weak | Cullinan Oncology, Inc. | Jeffrey Alan Jones Chief Medical Officer | $66k 4,582 shares | -3% | |
| 18Weak | Cullinan Oncology, Inc. | Jennifer Michaelson Chief Scientific Officer | $77k 5,353 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.